ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Companies

Celltrion plans $500m factory in Wuhan to tap China drug market

Korean biotech company eyes local talent in first overseas production move

Celltrion's plant in Incheon: The South Korean drugmaker has chosen China's Wuhan as the site for its first overseas factory.   © Reuters

SEOUL -- South Korean drugmaker Celltrion will build its first overseas factory in China, the company said Tuesday, as it prepares to start contract manufacturing in the country.

Construction in the central Chinese city of Wuhan begins during the first half of this year, with at least 600 billion won ($514 million) to be invested by 2025.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more